Live News REGULATION L impact Jul 15, 2026, 09:09 PM UTC

ALDX - Aldeyra Therapeutics To Request FDA Type D Meeting On NDA Of Reproxalap Resubmission By End Of Q3 2026 per SEC filing

ALDX - Aldeyra Therapeutics To Request FDA Type D Meeting On NDA Of Reproxalap Resubmission By End Of Q3 2026 per SEC filing

SquawkNews Newsroom

ALDX - Aldeyra Therapeutics To Request FDA Type D Meeting On NDA Of Reproxalap Resubmission By End Of Q3 2026 per SEC filing